Back

Rationale and design of ACO-SWITCH - a phase 4 study evaluating serum transthyretin levels in patients with ATTR-CM who switched from tafamidis to acoramidis

10 May 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis: therapeutic strategies and clinical outcomes Cardiac Amyloidosis HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Roman Pfister

Cologne University Hospital - Heart Center, Cologne (Germany)

4 More presentations in this session

Presentation thumbnail
Influence of Vutrisiran on Systolic Blood Pressure in ATTR-CM: HELIOS-B
Doctor A. Sheikh (London, GB)
Abstract Slides
Presentation thumbnail
Anchored matching-adjusted indirect comparison of acoramidis (ATTRibute-CM) vs tafamidis (ATTR-ACT) for risk of cardiovascular-related hospitalization, all-cause mortality and safety in ATTR-CM
Doctor E. Joyce (Dublin, IE)
Abstract Slides
Presentation thumbnail
Acoramidis treatment attenuates the rise in N-terminal pro-B-type natriuretic peptide from baseline to month 30 compared with placebo across participant subgroups in ATTRibute-CM
Doctor M. Fontana (London, GB)
Abstract Slides
Presentation thumbnail
Longitudinal changes in PYP heart-to-contralateral lung ratio and echocardiographic diastolic parameters in ATTR cardiac amyloidosis treated with tafamidis
Doctor R. Gabarin (London, CA)
Abstract Slides

Access the full session

Session thumbnail
Cardiac amyloidosis: therapeutic strategies and clinical outcomes

The Event

Event poster

Heart Failure 2026

10 May 2026 15:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources